Eintrag weiter verarbeiten
Online-Ressource

Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel: Cancers
Personen und Körperschaften: Aust, Stefanie, Schwameis, Richard, Gagic, Tamara, Müllauer, Leonhard, Langthaler, Eva, Prager, Gerald, Grech, Christina, Reinthaller, Alexander, Krainer, Michael, Pils, Dietmar, Grimm, Christoph, Polterauer, Stephan
In: Cancers, 12, 2020, 3, S. 548
Format: E-Article
Sprache: Englisch
veröffentlicht:
MDPI AG
Schlagwörter:
Cancer Research
Oncology
author_facet Aust, Stefanie
Schwameis, Richard
Gagic, Tamara
Müllauer, Leonhard
Langthaler, Eva
Prager, Gerald
Grech, Christina
Reinthaller, Alexander
Krainer, Michael
Pils, Dietmar
Grimm, Christoph
Polterauer, Stephan
Aust, Stefanie
Schwameis, Richard
Gagic, Tamara
Müllauer, Leonhard
Langthaler, Eva
Prager, Gerald
Grech, Christina
Reinthaller, Alexander
Krainer, Michael
Pils, Dietmar
Grimm, Christoph
Polterauer, Stephan
author Aust, Stefanie
Schwameis, Richard
Gagic, Tamara
Müllauer, Leonhard
Langthaler, Eva
Prager, Gerald
Grech, Christina
Reinthaller, Alexander
Krainer, Michael
Pils, Dietmar
Grimm, Christoph
Polterauer, Stephan
spellingShingle Aust, Stefanie
Schwameis, Richard
Gagic, Tamara
Müllauer, Leonhard
Langthaler, Eva
Prager, Gerald
Grech, Christina
Reinthaller, Alexander
Krainer, Michael
Pils, Dietmar
Grimm, Christoph
Polterauer, Stephan
Cancers
Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
Cancer Research
Oncology
author_sort aust, stefanie
spelling Aust, Stefanie Schwameis, Richard Gagic, Tamara Müllauer, Leonhard Langthaler, Eva Prager, Gerald Grech, Christina Reinthaller, Alexander Krainer, Michael Pils, Dietmar Grimm, Christoph Polterauer, Stephan 2072-6694 MDPI AG Cancer Research Oncology http://dx.doi.org/10.3390/cancers12030548 <jats:p>Background: Treating cancer according to its molecular alterations (i.e., targeted treatment, TT) is the goal of precision medicine tumor boards (PTBs). Their clinical applicability has been evaluated for ovarian cancer patients in this analysis. Methods: All consecutive ovarian cancer patients discussed in a PTB at the Medical University of Vienna, Austria, from April 2015 to April 2019 were included (n = 44). Results: In 38/44 (86%) cases, at least one mutation, deletion or amplification was detected. The most frequently altered genes were p53 (64%), PI3K pathway (18%), KRAS (14%), BRCA1 (11%) and BRCA2 (2%). In 31 patients (70%) a TT was recommended. A total of 12/31 patients (39%) received the recommended therapy. Median time from indication for PTB to TT start was 65 days (15–216). Median time to treatment failure was 2.7 months (0.2–13.2). Clinical benefit rate (CBR) was 42%. Reasons for treatment discontinuation were disease progression (42%), poor performance status (PS &gt; 2; 25%), death (17%) or treatment related side effects (8%). In 61% the TT was not administered—mainly due to PS &gt; 2. Conclusion: Even though a TT recommendation can be derived frequently, clinical applicability remains limited due to poor patients’ general condition after exploitation of standard treatment. However, we observed antitumor activity in a substantial number of heavily pretreated patients.</jats:p> Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer Cancers
doi_str_mv 10.3390/cancers12030548
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzM5MC9jYW5jZXJzMTIwMzA1NDg
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzM5MC9jYW5jZXJzMTIwMzA1NDg
institution DE-D275
DE-Bn3
DE-Brt1
DE-D161
DE-Zwi2
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
imprint MDPI AG, 2020
imprint_str_mv MDPI AG, 2020
issn 2072-6694
issn_str_mv 2072-6694
language English
mega_collection MDPI AG (CrossRef)
match_str aust2020precisionmedicinetumorboardsclinicalapplicabilityofpersonalizedtreatmentconceptsinovariancancer
publishDateSort 2020
publisher MDPI AG
recordtype ai
record_format ai
series Cancers
source_id 49
title Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
title_unstemmed Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
title_full Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
title_fullStr Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
title_full_unstemmed Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
title_short Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
title_sort precision medicine tumor boards: clinical applicability of personalized treatment concepts in ovarian cancer
topic Cancer Research
Oncology
url http://dx.doi.org/10.3390/cancers12030548
publishDate 2020
physical 548
description <jats:p>Background: Treating cancer according to its molecular alterations (i.e., targeted treatment, TT) is the goal of precision medicine tumor boards (PTBs). Their clinical applicability has been evaluated for ovarian cancer patients in this analysis. Methods: All consecutive ovarian cancer patients discussed in a PTB at the Medical University of Vienna, Austria, from April 2015 to April 2019 were included (n = 44). Results: In 38/44 (86%) cases, at least one mutation, deletion or amplification was detected. The most frequently altered genes were p53 (64%), PI3K pathway (18%), KRAS (14%), BRCA1 (11%) and BRCA2 (2%). In 31 patients (70%) a TT was recommended. A total of 12/31 patients (39%) received the recommended therapy. Median time from indication for PTB to TT start was 65 days (15–216). Median time to treatment failure was 2.7 months (0.2–13.2). Clinical benefit rate (CBR) was 42%. Reasons for treatment discontinuation were disease progression (42%), poor performance status (PS &gt; 2; 25%), death (17%) or treatment related side effects (8%). In 61% the TT was not administered—mainly due to PS &gt; 2. Conclusion: Even though a TT recommendation can be derived frequently, clinical applicability remains limited due to poor patients’ general condition after exploitation of standard treatment. However, we observed antitumor activity in a substantial number of heavily pretreated patients.</jats:p>
container_issue 3
container_start_page 0
container_title Cancers
container_volume 12
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792347836245868548
geogr_code not assigned
last_indexed 2024-03-01T18:01:36.505Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Precision+Medicine+Tumor+Boards%3A+Clinical+Applicability+of+Personalized+Treatment+Concepts+in+Ovarian+Cancer&rft.date=2020-02-27&genre=article&issn=2072-6694&volume=12&issue=3&pages=548&jtitle=Cancers&atitle=Precision+Medicine+Tumor+Boards%3A+Clinical+Applicability+of+Personalized+Treatment+Concepts+in+Ovarian+Cancer&aulast=Polterauer&aufirst=Stephan&rft_id=info%3Adoi%2F10.3390%2Fcancers12030548&rft.language%5B0%5D=eng
SOLR
_version_ 1792347836245868548
author Aust, Stefanie, Schwameis, Richard, Gagic, Tamara, Müllauer, Leonhard, Langthaler, Eva, Prager, Gerald, Grech, Christina, Reinthaller, Alexander, Krainer, Michael, Pils, Dietmar, Grimm, Christoph, Polterauer, Stephan
author_facet Aust, Stefanie, Schwameis, Richard, Gagic, Tamara, Müllauer, Leonhard, Langthaler, Eva, Prager, Gerald, Grech, Christina, Reinthaller, Alexander, Krainer, Michael, Pils, Dietmar, Grimm, Christoph, Polterauer, Stephan, Aust, Stefanie, Schwameis, Richard, Gagic, Tamara, Müllauer, Leonhard, Langthaler, Eva, Prager, Gerald, Grech, Christina, Reinthaller, Alexander, Krainer, Michael, Pils, Dietmar, Grimm, Christoph, Polterauer, Stephan
author_sort aust, stefanie
container_issue 3
container_start_page 0
container_title Cancers
container_volume 12
description <jats:p>Background: Treating cancer according to its molecular alterations (i.e., targeted treatment, TT) is the goal of precision medicine tumor boards (PTBs). Their clinical applicability has been evaluated for ovarian cancer patients in this analysis. Methods: All consecutive ovarian cancer patients discussed in a PTB at the Medical University of Vienna, Austria, from April 2015 to April 2019 were included (n = 44). Results: In 38/44 (86%) cases, at least one mutation, deletion or amplification was detected. The most frequently altered genes were p53 (64%), PI3K pathway (18%), KRAS (14%), BRCA1 (11%) and BRCA2 (2%). In 31 patients (70%) a TT was recommended. A total of 12/31 patients (39%) received the recommended therapy. Median time from indication for PTB to TT start was 65 days (15–216). Median time to treatment failure was 2.7 months (0.2–13.2). Clinical benefit rate (CBR) was 42%. Reasons for treatment discontinuation were disease progression (42%), poor performance status (PS &gt; 2; 25%), death (17%) or treatment related side effects (8%). In 61% the TT was not administered—mainly due to PS &gt; 2. Conclusion: Even though a TT recommendation can be derived frequently, clinical applicability remains limited due to poor patients’ general condition after exploitation of standard treatment. However, we observed antitumor activity in a substantial number of heavily pretreated patients.</jats:p>
doi_str_mv 10.3390/cancers12030548
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzM5MC9jYW5jZXJzMTIwMzA1NDg
imprint MDPI AG, 2020
imprint_str_mv MDPI AG, 2020
institution DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229
issn 2072-6694
issn_str_mv 2072-6694
language English
last_indexed 2024-03-01T18:01:36.505Z
match_str aust2020precisionmedicinetumorboardsclinicalapplicabilityofpersonalizedtreatmentconceptsinovariancancer
mega_collection MDPI AG (CrossRef)
physical 548
publishDate 2020
publishDateSort 2020
publisher MDPI AG
record_format ai
recordtype ai
series Cancers
source_id 49
spelling Aust, Stefanie Schwameis, Richard Gagic, Tamara Müllauer, Leonhard Langthaler, Eva Prager, Gerald Grech, Christina Reinthaller, Alexander Krainer, Michael Pils, Dietmar Grimm, Christoph Polterauer, Stephan 2072-6694 MDPI AG Cancer Research Oncology http://dx.doi.org/10.3390/cancers12030548 <jats:p>Background: Treating cancer according to its molecular alterations (i.e., targeted treatment, TT) is the goal of precision medicine tumor boards (PTBs). Their clinical applicability has been evaluated for ovarian cancer patients in this analysis. Methods: All consecutive ovarian cancer patients discussed in a PTB at the Medical University of Vienna, Austria, from April 2015 to April 2019 were included (n = 44). Results: In 38/44 (86%) cases, at least one mutation, deletion or amplification was detected. The most frequently altered genes were p53 (64%), PI3K pathway (18%), KRAS (14%), BRCA1 (11%) and BRCA2 (2%). In 31 patients (70%) a TT was recommended. A total of 12/31 patients (39%) received the recommended therapy. Median time from indication for PTB to TT start was 65 days (15–216). Median time to treatment failure was 2.7 months (0.2–13.2). Clinical benefit rate (CBR) was 42%. Reasons for treatment discontinuation were disease progression (42%), poor performance status (PS &gt; 2; 25%), death (17%) or treatment related side effects (8%). In 61% the TT was not administered—mainly due to PS &gt; 2. Conclusion: Even though a TT recommendation can be derived frequently, clinical applicability remains limited due to poor patients’ general condition after exploitation of standard treatment. However, we observed antitumor activity in a substantial number of heavily pretreated patients.</jats:p> Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer Cancers
spellingShingle Aust, Stefanie, Schwameis, Richard, Gagic, Tamara, Müllauer, Leonhard, Langthaler, Eva, Prager, Gerald, Grech, Christina, Reinthaller, Alexander, Krainer, Michael, Pils, Dietmar, Grimm, Christoph, Polterauer, Stephan, Cancers, Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer, Cancer Research, Oncology
title Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
title_full Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
title_fullStr Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
title_full_unstemmed Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
title_short Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
title_sort precision medicine tumor boards: clinical applicability of personalized treatment concepts in ovarian cancer
title_unstemmed Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
topic Cancer Research, Oncology
url http://dx.doi.org/10.3390/cancers12030548